Pharmaceutical

Santhera and Catalyst to market DMD drug vamorolone in North America

The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.

Jul 19, 2023 - 20:00
Santhera and Catalyst to market DMD drug vamorolone in North America
The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.
Read the original article

Tags:

Previous Article

US DoD enlists VitriVax to develop one-shot vaccine for melioidosis

Next Article

Novartis reports 7% rise in Q2 2023 net sales

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC

EC upgrades approval for J&J’s Rybrevant/chemotherapy c...

Aug 29, 2024

STAT+: Pharmalittle: Novo Nordisk spent $11 million on doctors to promote Ozempic and similar drugs; China offers foreign drugmakers an olive branch

STAT+: Pharmalittle: Novo Nordisk spent $11 million on ...

Jul 6, 2023

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

Don’t ignore potential microbial causes of Alzheimer’s ...

May 3, 2023